Patents by Inventor Konstantin Galaktionov

Konstantin Galaktionov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7005258
    Abstract: Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. More specifically, the invention relates to inhibiting transcription or translation of mammalian CDC25A genes using oligonucleotides.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: February 28, 2006
    Assignee: The National Institutes of Health
    Inventors: David H. Beach, Konstantin Galaktionov
  • Patent number: 6322975
    Abstract: The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: November 27, 2001
    Inventors: David H. Beach, Konstantin Galaktionov
  • Publication number: 20010044102
    Abstract: The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.
    Type: Application
    Filed: January 15, 1999
    Publication date: November 22, 2001
    Inventors: DAVID H. BEACH, KONSTANTIN GALAKTIONOV
  • Patent number: 6037136
    Abstract: The present invention derives from the discovery that CDC25 phosphatases and Raf proteins are able to physically interact to form protein-protein complexes, with the Raf protein mediating the activation of CDC25 phosphatases. The present invention provides both cell-free and cellular assays for detecting agents which modulate the ras-dependent activation of CDC25, as for example, by affecting the binding of a CDC25 protein with Raf, or Raf-associated complexes. Also disclosed is a method for transforming/immortalizing cells, particularly primary cell cultures.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: March 14, 2000
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Konstantin Galaktionov, Catherine Jessus
  • Patent number: 5994074
    Abstract: Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: November 30, 1999
    Assignee: Cold Spring Harbor Laboratories
    Inventors: David H. Beach, Konstantin Galaktionov
  • Patent number: 5861249
    Abstract: The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: January 19, 1999
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Konstantin Galaktionov
  • Patent number: 5770423
    Abstract: Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: June 23, 1998
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Konstantin Galaktionov
  • Patent number: 5756335
    Abstract: Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2 are described. As a result of this work, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases or through alteration of the interaction of components of MPF. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: May 26, 1998
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Konstantin Galaktionov
  • Patent number: 5695950
    Abstract: A method of identifying compounds or molecules which alter (enhance or inhibit) stimulation of kinase activity of pre-MPF and, thus, alter (enhance or inhibit) activation of MPF and entry into mitosis. The present method thus makes it possible to identify compounds or molecules which can be administered to regulate the cell cycle; such compounds are also the subject of this invention.
    Type: Grant
    Filed: January 31, 1994
    Date of Patent: December 9, 1997
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Konstantin Galaktionov
  • Patent number: 5441880
    Abstract: Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2.As a result of the work described herein, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases, particularly cdc25 phosphatase, and B-type cyclin or through alteration of the interaction of components of MPF, particularly the association of cdc25 with cyclin, cdc2 or the cdc2/cyclin B complex. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: August 15, 1995
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Konstantin Galaktionov